Clinical-stage precision health company EXACT Therapeutics AS (EXACT-Tx) (Euronext Growth Oslo:EXTX) on Tuesday reported positive results from the dose escalation phase of the ACTIVATE trial, which is evaluating Acoustic Cluster Therapy (ACT) in conjunction with chemotherapy for the treatment of liver metastasis in patients with advanced solid tumours.

Findings demonstrate promising safety and anticancer activity outcomes in this hart-to-treat patient group.

Dr. Amir Snapir, CMO of EXACT Therapeutics, expressed optimism about the results, highlighting the tolerability of ACT treatment and its potential to enhance the effectiveness of chemotherapy.

The dose escalation part of the trial involved eight patients and showed that combining ACT treatment with FOLFOX or FOLFIRI was well-tolerated, with no unexpected acute or delayed side effects. Positive anticancer responses were observed in almost all assessable patients, underscoring ACT's ability to augment the anticancer response to Standard of Care chemotherapy.